<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?properties manuscript?><?origin nihpa?><?iso-abbr J Parkinsons Dis Alzheimers Dis?><?submitter-system nihms?><?submitter-userid 6907880?><?submitter-authority myNCBI?><?submitter-login ashwin_avens?><?submitter-name Avens Publishing Group?><?domain nihpa?><front><journal-meta><journal-id journal-id-type="nlm-journal-id">101645837</journal-id><journal-id journal-id-type="pubmed-jr-id">43243</journal-id><journal-id journal-id-type="nlm-ta">J Parkinsons Dis Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Parkinsons Dis Alzheimers Dis</journal-id><journal-title-group><journal-title>Journal of Parkinson's disease and Alzheimer's disease</journal-title></journal-title-group><issn pub-type="epub">2376-922X</issn></journal-meta><article-meta><article-id pub-id-type="pmcid">4772657</article-id><article-id pub-id-type="doi">10.13188/2376-922X.1000010</article-id><article-id pub-id-type="manuscript">nihpa721348</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Alternative Splicing in Alzheimer&#x02019;s Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Love</surname><given-names>Julia E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hayden</surname><given-names>Eric J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rohn</surname><given-names>Troy T.</given-names></name><xref ref-type="corresp" rid="cor1">*</xref></contrib><aff id="A1">Department of Biological Sciences, Science Building, Boise State
University, USA</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label><bold>Address for Correspondence</bold> Troy T.
Rohn, Ph.D., Department of Biological Sciences, Science Building, Boise State
University, 1910 University Drive, Boise, ID 83725, USA, Tel: 208-426-2396; Fax:
208-426-1040; <email>trohn@boisestate.edu</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>11</day><month>9</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>15</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>8</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>3</month><year>2016</year></pub-date><volume>2</volume><issue>2</issue><elocation-id>6</elocation-id><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly
cited.</license-p></license></permissions><self-uri xlink:href="http://www.avensonline.org/fulltextarticles/jpa-2376-922x-02-0010.html"/><abstract><p id="P1">Neurodegenerative diseases have a variety of different genes contributing
to their underlying pathology. Unfortunately, for many of these diseases it is
not clear how changes in gene expression affect pathology. Transcriptome
analysis of neurodegenerative diseases using ribonucleic acid sequencing (RNA
Seq) and real time quantitative polymerase chain reaction (RT-qPCR) provides for
a platform to allow investigators to determine the contribution of various genes
to the disease phenotype. In Alzheimer&#x02019;s disease (AD) there are several
candidate genes reported that may be associated with the underlying pathology
and are, in addition, alternatively spliced. Thus, AD is an ideal disease to
examine how alternative splicing may affect pathology. In this context, genes of
particular interest to AD pathology include the amyloid precursor protein
(<italic>APP</italic>), <italic>TAU</italic>, and apolipoprotein E
(<italic>APOE</italic>). Here, we review the evidence of alternative
splicing of these genes in normal and AD patients, and recent therapeutic
approaches to control splicing.</p></abstract><kwd-group><kwd>Alzheimer&#x02019;s disease</kwd><kwd>Alternative splicing</kwd><kwd>RNA Sequencing</kwd><kwd>Amyloid precursor protein</kwd><kwd>Tau</kwd><kwd>Apo lipoprotein E4</kwd><kwd>Antisense oligonucleotides</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="S1"><title>Introduction</title><sec id="S2"><title>Alzheimer&#x02019;s disease</title><p id="P2">Alzheimer&#x02019;s disease (AD) is the most common cause of dementia in
the U.S.A. and is characterized by a progressive decline in various cognitive
functions [<xref rid="R1" ref-type="bibr">1</xref>]. Common cognitive
impairments associated with AD are lowered performance in memory, attention,
language, visuospatial skills, and in executing tasks that were previously
performed with ease [<xref rid="R2" ref-type="bibr">2</xref>]. The
neuropathology of AD is characterized by both the accumulation of toxic,
extracellular beta-amyloid deposition and neurofibrillary tangles resulting from
an accumulation of hyperphosphorylated <italic>tau</italic> protein [<xref rid="R3" ref-type="bibr">3</xref>]. Age is the most important risk factor in
AD, but the decline in cognitive function is individual-specific and is
influenced by environmental factors, individual experience, and genetic
pre-disposition [<xref rid="R4" ref-type="bibr">4</xref>].</p><p id="P3">Genetic risk factors associated with early onset AD (manifestation of AD
prior to age 60) typically involve mutations in the amyloid precursor protein
(<italic>APP</italic>) gene, presenilin 1 (<italic>PSEN1</italic>) gene, and
presenilin2 (<italic>PSEN2</italic>) gene [<xref rid="R5" ref-type="bibr">5</xref>]. These genes ultimately enhance beta amyloid peptide production
[<xref rid="R6" ref-type="bibr">6</xref>]. Different genetic risk factors
are associated with both sporadic and late onset AD (cases 65 and older).
Candidate genes include <italic>A2M</italic> (encoding alpha-2-macroglobulin),
<italic>ABCA1</italic> and <italic>2</italic> (encoding ATP-binding cassette
transporters 1 and 2, respectively), <italic>CLU</italic> (encoding clusterin),
<italic>PICALM</italic> (encoding the phosphatidylinositol binding clathrin
assembly protein), <italic>SORL1</italic> (encoding sortilin-related receptor
gene), and <italic>TREM2</italic> (triggering receptor expressed on myeloid
cells 2) [<xref rid="R7" ref-type="bibr">7</xref>]. <italic>APOE, APP</italic>,
and <italic>tau</italic> also have alleles associated with late onset AD and are
of particular interest for this review because they show disease specific
alternative splicing variants. In these genes, alternatively spliced variants
also show different levels of protein expression, which may in turn have
important effects upon protein aggregation [<xref rid="R8" ref-type="bibr">8</xref>&#x02013;<xref rid="R10" ref-type="bibr">10</xref>]. Understanding
varying gene expression could ultimately answer questions about AD pathogenesis
and identify possible targets for disease treatment. As proteomic and
transcriptomic technologies advance, there is now the potential to identify
neurodegenerative-specific changes in postmortem brain tissues. Using these
approaches could be useful in understanding protein aggregation in AD and the
underlying pathology of AD, which is currently unresolved.</p></sec></sec><sec id="S3"><title>Alternative Splicing in Alzheimer&#x02019;s disease</title><sec id="S4"><title>Regulators of alternative splicing</title><p id="P4">Alternative splicing is a main contributor to the complexity of organisms
and their tissues. For example, in humans roughly 95% of multi-exonic
genes are alternatively spliced resulting in 100,000 proteins in the human
genome [<xref rid="R11" ref-type="bibr">11</xref>]. Alternative splicing occurs
co- or post-transcriptionally resulting in multiple mRNA variants from a single
gene (<xref ref-type="fig" rid="F1">Figure 1</xref>). Alternative splicing is
carried out by a spliceosome, which is made up of 5 small nuclear RNA (snRNA)
molecules U1, U2, U4, U5, U6, and numerous proteins [<xref rid="R9" ref-type="bibr">9</xref>]. In addition, splicing is regulated by specific
nucleotide sequences found within the mRNA (cis-elements). These elements
include exonic splicing enhancers, exonic splicing silencers, and intronic
splicing silencers [<xref rid="R9" ref-type="bibr">9</xref>]. In addition to
cis-elements, trans-acting factors are a group of proteins that bind to
cis-elements and are composed of serine and arginine rich (SR) proteins and
heterogeneous nuclear ribonucleoproteins (hnRNPs). The presence of cis-elements
and the tissue-specific expression of trans-acting factors regulate overall
alternative splicing patterns [<xref rid="R12" ref-type="bibr">12</xref>].
Mutations in the spliceosomal machinery, cis-elements and trans-acting factors
may contribute to the onset of disease. Several examples of the specific types
of alternative splicing that may occur in AD are presented in <xref ref-type="fig" rid="F1">Figure 1</xref>.</p></sec><sec id="S5"><title>Brain tissue specific alternative splicing</title><p id="P5">Alternative splicing is tissue specific, and especially important for
brain tissue. The brain expresses more alternatively spliced genes than any
other tissue according to current transcriptome analyses, a fact that likely
contributes to the complexity of this organ [<xref rid="R11" ref-type="bibr">11</xref>]. Alternative splicing can be influenced by both the aging
process and/ or environmental factors [<xref rid="R13" ref-type="bibr">13</xref>]. In AD, differential expression of genes and alternative splicing
can potentially impact different signaling pathways. For example, genes that are
over expressed in AD are genes associated with synaptogenesis, transmission,
post-synaptic density, and long-term potentiation, all of which may contribute
to disease pathogenesis associated with AD [<xref rid="R12" ref-type="bibr">12</xref>]. An example of up regulation of a gene in AD due to alternative
splicing can be seen in immune-related pathways triggering increased
neuro-inflammatory responses in the aging hippocampus [<xref rid="R12" ref-type="bibr">12</xref>]. On the other hand, it has been hypothesized that down
regulation of specific genes in AD might lead to a compromise of DNA repair
mechanisms consequently affecting chromosomal stability [<xref rid="R10" ref-type="bibr">10</xref>]. For example, over expression of amyloid-beta precursor
protein-binding family B, member 2 (APBB2) can lead to cell cycle delays that
cause down regulation of thymidilate synthase, an enzyme normally responsible
for thymine formation. The decrease in thymine production in turn can lead to
DNA damage and to a decrease in the ability to repair damaged DNA changing gene
expression [<xref rid="R14" ref-type="bibr">14</xref>]. Changes in gene
expression, either up or down in certain pathways supports the complexity of the
role alternative splicing in AD (<xref ref-type="table" rid="T1">Table
1</xref>).</p><p id="P6">The application of transcriptome analysis in AD may provide insight into
possible genes associated with the disease through RNA alternative splicing,
antisense oligonucleotides, small nuclear ribonucleoproteins, and microRNAs. In
this review, we will focus on what is known about normal and abnormal
alternative splicing in some key genes associated with AD. Current research
suggests that future transcriptome analysis will be important for determining
how different splice variants could be used as diagnostic tools and targets for
disease treatment.</p></sec></sec><sec id="S6"><title>Alternative Splicing and &#x003b2;-amyloid Processing</title><p id="P7">Mutations that occur in <italic>PSEN1, PSEN2</italic>, and
<italic>APP</italic> are most associated with early onset AD and affect the
deposition of oligomeric &#x003b2;-amyloid peptides, which is the earliest known
step in the disease pathology of AD [<xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R19" ref-type="bibr">19</xref>]. More specifically, PSEN1 and PSEN2 are
part of the gamma secretase complex and are involved in the cleavage of APP [<xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R19" ref-type="bibr">19</xref>].
Incorrect cleavage of APP by the gamma secretase complex leads to the accumulation
of toxic &#x003b2;-amyloid peptide [<xref rid="R20" ref-type="bibr">20</xref>].
Mutations found in <italic>PSEN1</italic> occur in intron 4 causing mis-splicing and
exclusion of all or part of exon 4 [<xref rid="R16" ref-type="bibr">16</xref>]. In
addition to this mis-splicing example, other mutations in <italic>PSEN1</italic> can
lead to alterations in the expression of &#x003b2;-amyloid [<xref rid="R21" ref-type="bibr">21</xref>]. Specifically for <italic>PSEN2</italic>, a splice variant
lacking exon 5 has been documented and is found in both early and late onset AD
[<xref rid="R22" ref-type="bibr">22</xref>]. However, little is known about how
this splice form contributes to disease pathology or progression.</p><p id="P8">By the use of ribonucleic acid sequencing (RNA-Seq), which quantifies the
transcriptional outputs of both coding and non-coding RNA in the brain, there have
been multiple transcription products presumed to be involved in the incorrect
processing of APP [<xref rid="R23" ref-type="bibr">23</xref>]. Incorrect processing
of APP leads to increased &#x003b2;-amyloid synthesis and accumulation. Alternative
splicing occurring in these genes could be a key factor affecting this process. For
example, RNA polymerase III has been proposed to transcribe a non-coding RNA that is
responsible for exon 8 exclusion in amyloid-beta precursor protein-binding family B,
member 2 (APBB2) [<xref rid="R10" ref-type="bibr">10</xref>]. APBB2 co-localizes
with the amyloid intracellular c-terminal domain (AICD) of APP [<xref rid="R24" ref-type="bibr">24</xref>]. <italic>APBB2</italic> has three protein
variants produced by alternative splicing (termed a,b, and c) and RNA polymerase III
is responsible for producing more of the &#x0201c;a and b&#x0201d;exon 8 variants
leading to exon 8 inclusion, while variant &#x0201c;c&#x0201d; results in exclusion
of exon 8. The non-coding RNA transcribed by RNA polymerase III alters the ratio of
alternative protein variants (a, b, and c) resulting in exon 8 inclusion and a
reduction in the total amount of &#x003b2;-amyloid released [<xref rid="R10" ref-type="bibr">10</xref>]. Attempts to regulate alternative splicing to promote exon
8 inclusion underscores the potential of APBB2 as a target for treatment and
prevention by decreasing &#x003b2;-amyloid release.</p><p id="P9">A second gene that contributes to &#x003b2;-amyloid aggregation is a group of
proteins called RNA binding protein fork head box (RBFox). RBFox proteins are trans
acting regulators of alternative splicing of the <italic>APP</italic> gene. The
action of RBFox leads to the inclusion or exclusion of exon 7 within the
<italic>APP</italic> gene. The inclusion of exon 7 is the dominant splice form
in neural tissue of AD patients, and may contribute to &#x003b2;-amyloid production
[<xref rid="R25" ref-type="bibr">25</xref>]. Moreover, <italic>APP</italic>
iso-forms containing exon 7 are elevated in AD brain tissue and can activate the
intracellular domain of <italic>APP</italic> as well as beta secretase [<xref rid="R26" ref-type="bibr">26</xref>]. Interestingly, the RBFox splice variant
that retains exon 8 has also been thought to be involved with &#x003b2;-amyloid
deposition in AD much like exon 7 [<xref rid="R25" ref-type="bibr">25</xref>]. There
is still little known about factors contributing to exon 8 inclusion or exclusion,
and further research is needed to examine the alternative splicing of the
<italic>APP</italic> gene and the role that RBFox proteins play in this process.
Elucidating the exact role that alternative splicing events play in enhancing the
production of &#x003b2;-amyloid could uncover new drug targets for the treatment of
AD.</p><p id="P10">A final example of an alternatively spliced gene resulting in incorrect APP
processing and increased &#x003b2;-amyloid production is clusterin
(<italic>CLU</italic>). Much like RBFox proteins, the function of clusterin and
the exon variant associated with AD is relatively unclear [<xref rid="R15" ref-type="bibr">15</xref>]. In the experiment conducted by M. Szymanski et al. a
single nucleotide polymorphism (SNP) in exon 1 promotes alternative splicing of a
transcript of clusterin that enhances clusterin function and is associated with
enhanced risk of AD [<xref rid="R15" ref-type="bibr">15</xref>]. Clusterin has been
demonstrated to play a role in &#x003b2;-amyloid uptake and degradation [<xref rid="R27" ref-type="bibr">27</xref>], regulation of soluble &#x003b2;-amyloid
levels across the blood-brain barrier [<xref rid="R28" ref-type="bibr">28</xref>],
and binding with high affinity to soluble &#x003b2;-amyloid [<xref rid="R29" ref-type="bibr">29</xref>]. Although there is general uncertainly with regards to the
mechanistic role of clusterin in AD pathology, there is direct evidence that
clusterin modifies &#x003b2;-amyloid metabolism and/or deposition. This evidence
comes from transgenic animal models comparing clusterin knockout mice with wild type
mice [<xref rid="R30" ref-type="bibr">30</xref>]. Additional research on alterative
splice variants of <italic>CLU</italic> could reveal the functional role of
clusterin in AD. In addition, finding other alternatively spliced genes that affect
either production of &#x003b2;-amyloid or its removal could provide valuable
information on the underlying pathology associated with AD.</p></sec><sec id="S7"><title>Alternative Splicing of the Microtubule-Associated Protein, Tau in
Alzheimer&#x02019;s disease</title><p id="P11">A key step in the pathogenesis associated with AD is the post-translational
modifications of <italic>tau</italic> including hyperphosphorylation, which leads to
the formation of neurofibrillary tangles [<xref rid="R31" ref-type="bibr">31</xref>]. Functionally, <italic>tau</italic> is characterized as a
microtubule-associated protein (MAP) and is important for stabilizing the
cytoskeleton by binding to microtubules. Hyperphosphorylation of
<italic>tau</italic> leads to a decrease binding affinity to microtubules and
subsequent self-aggregation of <italic>tau</italic> into beta-sheet structures
termed paired-helical filaments [<xref rid="R31" ref-type="bibr">31</xref>]. Exons
2, 3 and 10 of the <italic>Tau</italic> gene are alternatively spliced resulting in
six known isoforms of <italic>Tau</italic> expressed in the brain [<xref rid="R17" ref-type="bibr">17</xref>]. Exon 10 encodes for the second
microtubule-binding repeat and the inclusion of exon 10 generates
<italic>tau</italic> isoforms with either three or four microtubule-binding
sites (referred to as 3R-<italic>tau</italic> or 4R <italic>tau</italic>) [<xref rid="R18" ref-type="bibr">18</xref>]. The inclusion of exon 10 produces
<italic>tau</italic> isoforms that are in a balanced ratio (1:1) in adult human
brains with 3R-<italic>tau</italic> being primarily produced during development and
the 4R-<italic>tau</italic> isoforms being produced in adulthood [<xref rid="R18" ref-type="bibr">18</xref>].</p><p id="P12">Serine/arginine (SR) rich proteins are one family of splicing factors
involved in the alternative splicing of <italic>tau</italic>. In this regard, one
such SR protein is SC35, which promotes exon 10 inclusion by acting on a SC35-like
enhancer at the 5&#x02019; end of the <italic>tau</italic> RNA transcript [<xref rid="R32" ref-type="bibr">32</xref>]. Interesting, the phosphorylation of SC35
by protein kinase A (PKA) prevents inclusion of exon 10 resulting in increased
expression of the 3R-<italic>tau</italic> isoform [<xref rid="R33" ref-type="bibr">33</xref>]. An unbalanced ratio of 3R-<italic>tau</italic> to
4R-<italic>tau</italic> is caused by down regulating the PKA phosphorylation
pathway, which in turn promotes exon 10 inclusion [<xref rid="R33" ref-type="bibr">33</xref>]. Previous studies have shown that inclusion of exon 10 generating
the 4R-<italic>tau</italic> isoform can lead to enhanced neurofibrillary tangles and
<italic>tau</italic> aggregation [<xref rid="R18" ref-type="bibr">18</xref>].</p><p id="P13">Previous studies have suggested that in AD there is a disproportionate level
of the 3R-<italic>tau</italic> isoform compared to the 4R form and this could be a
key factor driving the formation of <italic>tau</italic> into paired helical
filaments (PHFs) [<xref rid="R34" ref-type="bibr">34</xref>,<xref rid="R35" ref-type="bibr">35</xref>]. Numerous other SR proteins have roles in regulating the
alternative splicing of the <italic>Tau</italic> gene including SRSF1, SC35, SRSR6,
and SRSF9 all of which promote exon 10 inclusion. Alternatively, the activity of
SRSF3, SRSF4, SRSF7, and SRSF11 suppress inclusion of exon 10 [<xref rid="R9" ref-type="bibr">9</xref>]. The actions of PKA on various SR proteins supports the
notion that this is a common mechanism to modulate alternative splicing events
[<xref rid="R9" ref-type="bibr">9</xref>]. It is possible that exon 10 of the
<italic>Tau</italic> gene is highly regulated by alternative splicing in order
to maintain the proper balance between 3R-<italic>tau</italic> and
4R-<italic>tau</italic> isoforms. Because of the important role of
phosphorylation in splice site selection in the <italic>Tau</italic> gene, it has
been proposed that controlling phosphorylation could be the basis to develop new
therapeutic opportunities [<xref rid="R36" ref-type="bibr">36</xref>].</p></sec><sec id="S8"><title>Alternative Splicing of the APOE4 gene in Alzheimer&#x02019;s disease</title><p id="P14"><italic>APOE4</italic> is a well-studied protein because the inheritance of
the <italic>APOE4</italic> allele represents the single greatest genetic risk factor
for late-onset AD. The <italic>APOE</italic> gene is polymorphic in human
populations, with three common alleles, termed E2, E3, and E4. Harboring the E2
allele is protective against onset, while the E3 allele is neutral in this regard.
In contrast carrying the E4 allele increases the risk of developing AD 4&#x02013;10
fold [<xref rid="R37" ref-type="bibr">37</xref>]. ApoE4 has been suggested to affect
both &#x003b2;-amyloid and neurofibrillary tangle pathology in AD [<xref rid="R38" ref-type="bibr">38</xref>,<xref rid="R39" ref-type="bibr">39</xref>].
ApoE4 is a major cholesterol transporter in the brain and cholesterol rich membrane
domains increase &#x003b2;-amyloid production by affecting &#x003b2; and
&#x003b3;-secretase complexes [<xref rid="R40" ref-type="bibr">40</xref>].</p><p id="P15">Recent studies have shown that the E4 isoform is more prone to proteolysis
than other APOE isoforms and this could be the reason for the increase in AD risk
through either a loss or gain of function (for recent review see [<xref rid="R38" ref-type="bibr">38</xref>]). Thus, proteolysis of apoE4 may lead to a
loss of function in its ability to remove &#x003b2;-amyloid and to transport
cholesterol [<xref rid="R38" ref-type="bibr">38</xref>]. On the other hand, apoE4
fragments from proteolysis could lead to a toxic gain of function. For example,
cleavage of apoE4 produces N- and C-terminal fragments that are neurotoxic in nature
[<xref rid="R41" ref-type="bibr">41</xref>&#x02013;<xref rid="R44" ref-type="bibr">44</xref>]. Tolar et al. showed that not only is a 22 kDa N-terminal
fragment of apoE4 neurotoxic, but that it is significantly more toxic than the same
fragment derived from the E3 isoform [<xref rid="R43" ref-type="bibr">43</xref>].
Unfortunately, much is still not known about the mechanism by which ApoE4
contributes to the pathogenesis of AD.</p><p id="P16">According to a genome wide association study (GWAS) utilizing cerebrospinal
fluid (CSF) from AD subjects, several single nucleotide polymorphisms (SNPs)
associated with <italic>APOE</italic> gene region of the brain were also associated
with <italic>tau</italic> and phosphorylated <italic>tau</italic>
(p<italic>tau</italic>) levels in the CSF. When cerebrospinal fluid levels of
&#x003b2;-amyloid 1&#x02013;42 levels were analyzed together with
<italic>tau</italic>/p<italic>tau</italic>, a significant correlation was found
with SNPs of <italic>APOE</italic> gene [<xref rid="R39" ref-type="bibr">39</xref>].
The authors of this study suggested that apoE variants could be modulating
&#x003b2;-amyloid 1&#x02013;42 levels as well as <italic>tau</italic> pathology. It
is known that SNPs located near splice sites have the ability to change the splicing
pattern of a gene [<xref rid="R45" ref-type="bibr">45</xref>].</p><p id="P17">Alternative splicing and alternative transcriptional promoter choice
produces three main isoforms of <italic>APOE4</italic> (<italic>APOE4-001,
-002</italic>, and -<italic>005</italic>) [<xref rid="R8" ref-type="bibr">8</xref>]. <italic>APOE-001</italic> and <italic>APOE-002</italic> isoforms
contain exon 1 while the <italic>APOE-005</italic> isoform is generated by a
promoter upstream of exon 2 [<xref rid="R8" ref-type="bibr">8</xref>]. Conflicting
results have been obtained on the predominance of one <italic>APOE4</italic> isoform
over the others. For example, RNA-Seq experiments originally suggested that the
<italic>APOE4-005</italic> transcript was up regulated in AD while the
<italic>APOE4-001</italic> isoform was down regulated [<xref rid="R8" ref-type="bibr">8</xref>]. However, Mills et al. was unable to confirm these results
via the use of real time-quantitative polymerase chain reaction (RT-qPCR) [<xref rid="R46" ref-type="bibr">46</xref>]. The reasoning behind these discrepancies
are not known but may be due to the possibility that RNA samples being taken from
different areas of the temporal lobe in the two studies showed differential
expression. In addition, the sample size in the Mills et al. study was 14 temporal
lobe samples, whereas in the Twine et al. study the sample size was 1 temporal lobe
sample. The findings from a small sample size in the Twine et al. study may be
leading to an exaggerated difference between these studies. Alternatively, it is
possible that the AD cases used in the two studies were not comparable in terms of
pathology [<xref rid="R46" ref-type="bibr">46</xref>]. Finally, due to the issue of
heterogeneity of the disease process in AD patients, the progression of the disease
most likely varies significantly between affected individuals expressing the
<italic>APOE4</italic> allele. Therefore, although the data support the notion
that <italic>APOE4</italic> is alternatively spiced additional studies are warranted
to address the degree to which splice variant of <italic>APOE4</italic> is up- or
down regulated in normal versus AD tissues and at different stages of the
disease.</p></sec><sec id="S9"><title>Targeting RNA as a Possible Treatment Strategy in Alzheimer&#x02019;s
disease</title><sec id="S10"><title>Antisense Oligonucleotides</title><p id="P18">A recent approach to developing RNA specific therapeutics involves the
use of short strings of nucleic acids that base pair to a target RNA molecule,
which are referred to generally as antisense oligonucleotides (ASO) [<xref rid="R47" ref-type="bibr">47</xref>]. Often, the backbone chemistry of ASOs
is modified to either encourage degradation of RNA or keep RNA from being
degraded [<xref rid="R47" ref-type="bibr">47</xref>]. In this manner, endogenous
RNA transcripts can be manipulated in numerous ways leading to alternative
splicing, translation inhibition, and microRNA hindrance [<xref rid="R47" ref-type="bibr">47</xref>]. ASOs used as drugs are most often employed in a manner
as to change levels of a target gene, and modulating alternative splicing is
emerging as one such approach [<xref rid="R48" ref-type="bibr">48</xref>]. As
previously mentioned, the U1 snRNA molecule plays a key role in alternative
splicing. U1 snRNA has an additional role to suppress the processing of
premature cleavage and polyadenylation of RNA [<xref rid="R49" ref-type="bibr">49</xref>]. Polyadenylation is the addition of a poly (A) tail to mRNA at
the 3&#x02019; end, which normally serves as a protective role preventing
enzymatic degradation. When U1 was inhibited by an ASO
(&#x0201c;morphlino&#x0201d;), premature cleavage and polyadenylation occurred
resulting in increased activity of U1 snRNA [<xref rid="R50" ref-type="bibr">50</xref>]. Such a process effectively changed the alternative splicing
pattern due to increased premature cleavage and polyadenylation [<xref rid="R8" ref-type="bibr">8</xref>]. These observations are suggestive of a
loss of U1 snRNA function in the AD brain, which in turn could promote the
alternative splicing of genes that contribute to the underlying pathology
associated with this disease [<xref rid="R50" ref-type="bibr">50</xref>].</p><p id="P19">One advantage that ASOs have in terms of therapeutic agents is their
ability to cross the blood brain barrier, a limiting factor for much CNS
therapeutics. An example of how ASOs can be applied to AD treatment is targeting
pathological <italic>tau</italic> in AD. In <italic>TAU</italic> knock-out
animal models, &#x003b2;-amyloid-induced cognitive loss was restored by
targeting ASOs to reduce the amount of <italic>tau</italic> protein [<xref rid="R51" ref-type="bibr">51</xref>]. Therefore, reducing
<italic>tau</italic> protein levels could be a therapeutic technique
achievable through ASOs [<xref rid="R51" ref-type="bibr">51</xref>]. In addition
to <italic>tau</italic>, ASOs have also been used to lower &#x003b2;-amyloid
loads in mutant mice over expressing human APP [<xref rid="R52" ref-type="bibr">52</xref>]. Following administration of ASOs, APP levels were reduced and
learning and memory was rescued [<xref rid="R52" ref-type="bibr">52</xref>].</p></sec></sec><sec sec-type="conclusions" id="S11"><title>Conclusion</title><p id="P20">Alternative splicing is an important post-transcriptional regulatory
mechanism during gene expression that results in a single gene coding for multiple
proteins. In AD, however, alternative splicing of the <italic>APP</italic>,
<italic>TAU</italic>, or the <italic>APOE4</italic> gene may contribute to the
disease pathology. Understanding the role of alternative splicing of AD-associated
genes may not only shed light on the possible molecular mechanisms underlying this
disease, but also for the pathology of other neurodegenerative diseases as well. As
RNA-Seq technology continues to advance, it will become easier to analyze AD as well
as other neurodegenerative diseases on a molecular level.</p></sec></body><back><ack id="S12"><title>Acknowledgement</title><p id="P21">This work was funded by National Institutes of Health Grant
1R15AG042781-01A1 to TTR. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.</p></ack><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>JL</given-names></name></person-group><article-title>Alzheimer&#x02019;s disease</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><fpage>56</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">15229308</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albert</surname><given-names>MS</given-names></name><name><surname>DeKosky</surname><given-names>ST</given-names></name><name><surname>Dickson</surname><given-names>D</given-names></name><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Feldman</surname><given-names>HH</given-names></name><etal/></person-group><article-title>The diagnosis of mild cognitive impairment due to
Alzheimer&#x02019;s disease: recommendations from the National Institute on
Aging-Alzheimer&#x02019;s Association workgroups on diagnostic guidelines
for Alzheimer&#x02019;s disease</article-title><source>Alzheimers Dement</source><year>2011</year><volume>7</volume><fpage>270</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">21514249</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>ST</given-names></name><name><surname>Klein</surname><given-names>WL</given-names></name></person-group><article-title>The A&#x003b2; oligomer hypothesis for synapse failure and memory
loss in Alzheimer&#x02019;s disease</article-title><source>Neurobiol Learn Mem</source><year>2011</year><volume>96</volume><fpage>529</fpage><lpage>543</lpage><pub-id pub-id-type="pmid">21914486</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>A</given-names></name></person-group><article-title>Epigenetic memory: the Lamarckian brain</article-title><source>EMBO J</source><year>2014</year><volume>33</volume><fpage>945</fpage><lpage>967</lpage><pub-id pub-id-type="pmid">24719207</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schellenberg</surname><given-names>GD</given-names></name><name><surname>Bird</surname><given-names>TD</given-names></name><name><surname>Wijsman</surname><given-names>EM</given-names></name><name><surname>Orr</surname><given-names>HT</given-names></name><name><surname>Anderson</surname><given-names>L</given-names></name><etal/></person-group><article-title>Genetic linkage evidence for a familial Alzheimer&#x02019;s
disease locus on chromosome 14</article-title><source>Science</source><year>1992</year><volume>258</volume><fpage>668</fpage><lpage>671</lpage><pub-id pub-id-type="pmid">1411576</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vetrivel</surname><given-names>KS</given-names></name><name><surname>Zhang</surname><given-names>YW</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Thinakaran</surname><given-names>G</given-names></name></person-group><article-title>Pathological and physiological functions of
presenilins</article-title><source>Mol Neurodegener</source><year>2006</year><volume>1</volume><fpage>4</fpage><pub-id pub-id-type="pmid">16930451</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alonso Vilatela</surname><given-names>ME</given-names></name><name><surname>Lopez-Lopez</surname><given-names>M</given-names></name><name><surname>Yescas-Gomez</surname><given-names>P</given-names></name></person-group><article-title>Genetics of Alzheimer&#x02019;s disease</article-title><source>Arch Med Res</source><year>2012</year><volume>43</volume><fpage>622</fpage><lpage>631</lpage><pub-id pub-id-type="pmid">23142261</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Twine</surname><given-names>NA</given-names></name><name><surname>Janitz</surname><given-names>K</given-names></name><name><surname>Wilkins</surname><given-names>MR</given-names></name><name><surname>Janitz</surname><given-names>M</given-names></name></person-group><article-title>Whole transcriptome sequencing reveals gene expression and
splicing differences in brain regions affected by Alzheimer&#x02019;s
disease</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e16266</fpage><pub-id pub-id-type="pmid">21283692</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qian</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name></person-group><article-title>Regulation of alternative splicing of tau exon 10</article-title><source>Neurosci Bull</source><year>2014</year><volume>30</volume><fpage>367</fpage><lpage>377</lpage><pub-id pub-id-type="pmid">24627328</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penna</surname><given-names>I</given-names></name><name><surname>Vassallo</surname><given-names>I</given-names></name><name><surname>Nizzari</surname><given-names>M</given-names></name><name><surname>Russo</surname><given-names>D</given-names></name><name><surname>Costa</surname><given-names>D</given-names></name><etal/></person-group><article-title>A novel snRNA-like transcript affects amyloidogenesis and cell
cycle progression through perturbation of Fe65L1 (APBB2) alternative
splicing</article-title><source>Biochim Biophys Acta</source><year>2013</year><volume>1833</volume><fpage>1511</fpage><lpage>1526</lpage><pub-id pub-id-type="pmid">23485396</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>JD</given-names></name><name><surname>Nalpathamkalam</surname><given-names>T</given-names></name><name><surname>Jacobs</surname><given-names>HI</given-names></name><name><surname>Janitz</surname><given-names>C</given-names></name><name><surname>Merico</surname><given-names>D</given-names></name><etal/></person-group><article-title>RNA-Seq analysis of the parietal cortex in Alzheimer&#x02019;s
disease reveals alternatively spliced isoforms related to lipid
metabolism</article-title><source>Neurosci Lett</source><year>2013</year><volume>536</volume><fpage>90</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">23305720</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stilling</surname><given-names>RM</given-names></name><name><surname>Benito</surname><given-names>E</given-names></name><name><surname>Gertig</surname><given-names>M</given-names></name><name><surname>Barth</surname><given-names>J</given-names></name><name><surname>Capece</surname><given-names>V</given-names></name><etal/></person-group><article-title>De-regulation of gene expression and alternative splicing affects
distinct cellular pathways in the aging hippocampus</article-title><source>Front Cell Neurosci</source><year>2014</year><volume>8</volume><fpage>373</fpage><pub-id pub-id-type="pmid">25431548</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karambataki</surname><given-names>M</given-names></name><name><surname>Malousi</surname><given-names>A</given-names></name><name><surname>Kouidou</surname><given-names>S</given-names></name></person-group><article-title>Risk-associated coding synonymous SNPs in type 2 diabetes and
neurodegenerative diseases: genetic silence and the underrated association
with splicing regulation and epigenetics</article-title><source>Mutat Res</source><year>2014</year><volume>770</volume><fpage>85</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">25771874</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruni</surname><given-names>P</given-names></name><name><surname>Minopoli</surname><given-names>G</given-names></name><name><surname>Brancaccio</surname><given-names>T</given-names></name><name><surname>Napolitano</surname><given-names>M</given-names></name><name><surname>Faraonio</surname><given-names>R</given-names></name><etal/></person-group><article-title>Fe65, a ligand of the Alzheimer&#x02019;s beta-amyloid precursor
protein, blocks cell cycle progression by down-regulating thymidylate
synthase expression</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>35481</fpage><lpage>35488</lpage><pub-id pub-id-type="pmid">12089154</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szymanski</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Bassett</surname><given-names>SS</given-names></name><name><surname>Avramopoulos</surname><given-names>D</given-names></name></person-group><article-title>Alzheimer&#x02019;s risk variants in the clusterin gene are
associated with alternative splicing</article-title><source>Transl Psychiatry</source><year>2011</year><volume>1</volume></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Jonghe</surname><given-names>C</given-names></name><name><surname>Cruts</surname><given-names>M</given-names></name><name><surname>Rogaeva</surname><given-names>EA</given-names></name><name><surname>Tysoe</surname><given-names>C</given-names></name><name><surname>Singleton</surname><given-names>A</given-names></name><etal/></person-group><article-title>Aberrant splicing in the presenilin-1 intron 4 mutation causes
presenile Alzheimer&#x02019;s disease by increased Abeta42
secretion</article-title><source>Hum Mol Genet</source><year>1999</year><volume>8</volume><fpage>1529</fpage><lpage>1540</lpage><pub-id pub-id-type="pmid">10401002</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreadis</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>WM</given-names></name><name><surname>Kosik</surname><given-names>KS</given-names></name></person-group><article-title>Structure and novel exons of the human tau gene</article-title><source>Biochemistry</source><year>1992</year><volume>31</volume><fpage>10626</fpage><lpage>10633</lpage><pub-id pub-id-type="pmid">1420178</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goedert</surname><given-names>M</given-names></name><name><surname>Spillantini</surname><given-names>MG</given-names></name><name><surname>Jakes</surname><given-names>R</given-names></name><name><surname>Rutherford</surname><given-names>D</given-names></name><name><surname>Crowther</surname><given-names>RA</given-names></name></person-group><article-title>Multiple isoforms of human microtubule-associated protein tau:
sequences and localization in neurofibrillary tangles of Alzheimer&#x02019;s
disease</article-title><source>Neuron</source><year>1989</year><volume>3</volume><fpage>519</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">2484340</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy-Lahad</surname><given-names>E</given-names></name><name><surname>Wijsman</surname><given-names>EM</given-names></name><name><surname>Nemens</surname><given-names>E</given-names></name><name><surname>Anderson</surname><given-names>L</given-names></name><name><surname>Goddard</surname><given-names>KA</given-names></name><etal/></person-group><article-title>A familial Alzheimer&#x02019;s disease locus on chromosome
1</article-title><source>Science</source><year>1995</year><volume>269</volume><fpage>970</fpage><lpage>973</lpage><pub-id pub-id-type="pmid">7638621</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baulac</surname><given-names>S</given-names></name><name><surname>LaVoie</surname><given-names>MJ</given-names></name><name><surname>Kimberly</surname><given-names>WT</given-names></name><name><surname>Strahle</surname><given-names>J</given-names></name><name><surname>Wolfe</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Functional gamma-secretase complex assembly in Golgi/trans-Golgi
network: interactions among presenilin, nicastrin, Aph1, Pen-2, and
gamma-secretase substrates</article-title><source>Neurobiol Dis</source><year>2003</year><volume>14</volume><fpage>194</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">14572442</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruts</surname><given-names>M</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name></person-group><article-title>Presenilin mutations in Alzheimer&#x02019;s
disease</article-title><source>Hum Mutat</source><year>1998</year><volume>11</volume><fpage>183</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">9521418</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>N</given-names></name><name><surname>Hori</surname><given-names>O</given-names></name><name><surname>Yamaguchi</surname><given-names>A</given-names></name><name><surname>Lambert</surname><given-names>JC</given-names></name><name><surname>Chartier-Harlin</surname><given-names>MC</given-names></name><etal/></person-group><article-title>A novel presenilin-2 splice variant in human Alzheimer&#x02019;s
disease brain tissue</article-title><source>J Neurochem</source><year>1999</year><volume>72</volume><fpage>2498</fpage><lpage>2505</lpage><pub-id pub-id-type="pmid">10349860</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutherland</surname><given-names>GT</given-names></name><name><surname>Janitz</surname><given-names>M</given-names></name><name><surname>Kril</surname><given-names>JJ</given-names></name></person-group><article-title>Understanding the pathogenesis of Alzheimer&#x02019;s disease:
will RNA-Seq realize the promise of transcriptomics?</article-title><source>J Neurochem</source><year>2011</year><volume>116</volume><fpage>937</fpage><lpage>946</lpage><pub-id pub-id-type="pmid">21175619</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Sudhof</surname><given-names>TC</given-names></name></person-group><article-title>Dissection of amyloid-beta precursor protein-dependent
transcriptional transactivation</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>24601</fpage><lpage>24611</lpage><pub-id pub-id-type="pmid">15044485</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alam</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Tsukahara</surname><given-names>T</given-names></name></person-group><article-title>Alternative splicing regulation of APP exon 7 by RBFox
proteins</article-title><source>Neurochem Int</source><year>2014</year><volume>78</volume><fpage>7</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">25125370</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belyaev</surname><given-names>ND</given-names></name><name><surname>Kellett</surname><given-names>KA</given-names></name><name><surname>Beckett</surname><given-names>C</given-names></name><name><surname>Makova</surname><given-names>NZ</given-names></name><name><surname>Revett</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>The transcriptionally active amyloid precursor protein (APP)
intracellular domain is preferentially produced from the 695 isoform of APP
in a {beta}-secretase-dependent pathway</article-title><source>J Biol Chem</source><year>2010</year><volume>285</volume><fpage>41443</fpage><lpage>41454</lpage><pub-id pub-id-type="pmid">20961856</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Clusterin in Alzheimer&#x02019;s disease: a player in the
biological behavior of amyloid-beta</article-title><source>Neurosci Bull</source><year>2014</year><volume>30</volume><fpage>162</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">24353014</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zlokovic</surname><given-names>BV</given-names></name><name><surname>Martel</surname><given-names>CL</given-names></name><name><surname>Matsubara</surname><given-names>E</given-names></name><name><surname>McComb</surname><given-names>JG</given-names></name><name><surname>Zheng</surname><given-names>G</given-names></name><etal/></person-group><article-title>Glycoprotein 330/megalin: probable role in receptor-mediated
transport of apolipoprotein J alone and in a complex with Alzheimer disease
amyloid beta at the blood-brain and blood-cerebrospinal fluid
barriers</article-title><source>Proc Natl Acad Sci U S A</source><year>1996</year><volume>93</volume><fpage>4229</fpage><lpage>4234</lpage><pub-id pub-id-type="pmid">8633046</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsubara</surname><given-names>E</given-names></name><name><surname>Frangione</surname><given-names>B</given-names></name><name><surname>Ghiso</surname><given-names>J</given-names></name></person-group><article-title>Characterization of apolipoprotein J-Alzheimer&#x02019;s A beta
interaction</article-title><source>J Biol Chem</source><year>1995</year><volume>270</volume><fpage>7563</fpage><lpage>7567</lpage><pub-id pub-id-type="pmid">7706304</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeMattos</surname><given-names>RB</given-names></name><name><surname>O&#x02019;Dell</surname><given-names>MA</given-names></name><name><surname>Parsadanian</surname><given-names>M</given-names></name><name><surname>Taylor</surname><given-names>JW</given-names></name><name><surname>Harmony</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Clusterin promotes amyloid plaque formation and is critical for
neuritic toxicity in a mouse model of Alzheimer&#x02019;s
disease</article-title><source>Proc Natl Acad Sci U S A</source><year>2002</year><volume>99</volume><fpage>10843</fpage><lpage>10848</lpage><pub-id pub-id-type="pmid">12145324</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alonso</surname><given-names>A</given-names></name><name><surname>Zaidi</surname><given-names>T</given-names></name><name><surname>Novak</surname><given-names>M</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><name><surname>Iqbal</surname><given-names>K</given-names></name></person-group><article-title>Hyperphosphorylation induces self-assembly of tau into tangles of
paired helical filaments/straight filaments</article-title><source>Proc Natl Acad Sci U S A</source><year>2001</year><volume>98</volume><fpage>6923</fpage><lpage>6928</lpage><pub-id pub-id-type="pmid">11381127</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qian</surname><given-names>W</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>N</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><etal/></person-group><article-title>Regulation of the alternative splicing of tau exon 10 by SC35 and
Dyrk1A</article-title><source>Nucleic Acids Res</source><year>2011</year><volume>39</volume><fpage>6161</fpage><lpage>6171</lpage><pub-id pub-id-type="pmid">21470964</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Jin</surname><given-names>N</given-names></name><name><surname>Qian</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Tan</surname><given-names>X</given-names></name><etal/></person-group><article-title>Cyclic AMP-dependent protein kinase enhances SC35-promoted Tau
exon 10 inclusion</article-title><source>Mol Neurobiol</source><year>2014</year><volume>49</volume><fpage>615</fpage><lpage>624</lpage><pub-id pub-id-type="pmid">24037441</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Espinoza</surname><given-names>M</given-names></name><name><surname>de Silva</surname><given-names>R</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Davies</surname><given-names>P</given-names></name></person-group><article-title>Differential incorporation of tau isoforms in Alzheimer&#x02019;s
disease</article-title><source>J Alzheimers Dis</source><year>2008</year><volume>14</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">18525123</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goedert</surname><given-names>M</given-names></name><name><surname>Jakes</surname><given-names>R</given-names></name></person-group><article-title>Mutations causing neurodegenerative tauopathies</article-title><source>Biochim Biophys Acta</source><year>2005</year><volume>1739</volume><fpage>240</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">15615642</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartmann</surname><given-names>AM</given-names></name><name><surname>Rujescu</surname><given-names>D</given-names></name><name><surname>Giannakouros</surname><given-names>T</given-names></name><name><surname>Nikolakaki</surname><given-names>E</given-names></name><name><surname>Goedert</surname><given-names>M</given-names></name><etal/></person-group><article-title>Regulation of alternative splicing of human tau exon 10 by
phosphorylation of splicing factors</article-title><source>Mol Cell Neurosci</source><year>2001</year><volume>18</volume><fpage>80</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">11461155</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisenstein</surname><given-names>M</given-names></name></person-group><article-title>Genetics: finding risk factors</article-title><source>Nature</source><year>2011</year><volume>475</volume><fpage>S20</fpage><lpage>S22</lpage><pub-id pub-id-type="pmid">21760580</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rohn</surname><given-names>TT</given-names></name></person-group><article-title>Proteolytic cleavage of apolipoprotein e4 as the keystone for the
heightened risk associated with Alzheimer&#x02019;s disease</article-title><source>Int J Mol Sci</source><year>2013</year><volume>14</volume><fpage>14908</fpage><lpage>14922</lpage><pub-id pub-id-type="pmid">23867607</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruchaga</surname><given-names>C</given-names></name><name><surname>Kauwe</surname><given-names>JS</given-names></name><name><surname>Harari</surname><given-names>O</given-names></name><name><surname>Jin</surname><given-names>SC</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><etal/></person-group><article-title>GWAS of cerebrospinal fluid tau levels identifies risk variants
for Alzheimer&#x02019;s disease</article-title><source>Neuron</source><year>2013</year><volume>78</volume><fpage>256</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">23562540</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Mullendorff</surname><given-names>K</given-names></name><name><surname>Dong</surname><given-names>L</given-names></name><name><surname>Giedt</surname><given-names>G</given-names></name><etal/></person-group><article-title>Apolipoprotein (apo) E4 enhances amyloid beta peptide production
in cultured neuronal cells: apoE structure as a potential therapeutic
target</article-title><source>Proc Natl Acad Sci U S A</source><year>2005</year><volume>102</volume><fpage>18700</fpage><lpage>18705</lpage><pub-id pub-id-type="pmid">16344478</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>XQ</given-names></name><name><surname>Wyss-Coray</surname><given-names>T</given-names></name><name><surname>Brecht</surname><given-names>WJ</given-names></name><name><surname>Sanan</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Apolipoprotein E fragments present in Alzheimer&#x02019;s disease
brains induce neurofibrillary tangle-like intracellular inclusions in
neurons</article-title><source>Proc Natl Acad Sci U S A</source><year>2001</year><volume>98</volume><fpage>8838</fpage><lpage>8843</lpage><pub-id pub-id-type="pmid">11447277</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>S</given-names></name><name><surname>ran Ma</surname><given-names>T</given-names></name><name><surname>Miranda</surname><given-names>RD</given-names></name><name><surname>Balestra</surname><given-names>ME</given-names></name><name><surname>Mahley</surname><given-names>RW</given-names></name><etal/></person-group><article-title>Lipid- and receptor-binding regions of apolipoprotein E4
fragments act in concert to cause mitochondrial dysfunction and
neurotoxicity</article-title><source>Proc Natl Acad Sci U S A</source><year>2005</year><volume>102</volume><fpage>18694</fpage><lpage>18699</lpage><pub-id pub-id-type="pmid">16344479</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tolar</surname><given-names>M</given-names></name><name><surname>Marques</surname><given-names>MA</given-names></name><name><surname>Harmony</surname><given-names>JA</given-names></name><name><surname>Crutcher</surname><given-names>KA</given-names></name></person-group><article-title>Neurotoxicity of the 22 kDa thrombin-cleavage fragment of
apolipoprotein E and related synthetic peptides is
receptor-mediated</article-title><source>J Neurosci</source><year>1997</year><volume>17</volume><fpage>5678</fpage><lpage>5686</lpage><pub-id pub-id-type="pmid">9221767</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrews-Zwilling</surname><given-names>Y</given-names></name><name><surname>Bien-Ly</surname><given-names>N</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Bernardo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Apolipoprotein E4 causes age- and Tau-dependent impairment of
GABAergic interneurons, leading to learning and memory deficits in
mice</article-title><source>J Neurosci</source><year>2010</year><volume>30</volume><fpage>13707</fpage><lpage>13717</lpage><pub-id pub-id-type="pmid">20943911</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faber</surname><given-names>K</given-names></name><name><surname>Glatting</surname><given-names>KH</given-names></name><name><surname>Mueller</surname><given-names>PJ</given-names></name><name><surname>Risch</surname><given-names>A</given-names></name><name><surname>Hotz-Wagenblatt</surname><given-names>A</given-names></name></person-group><article-title>Genome-wide prediction of splice-modifying SNPs in human genes
using a new analysis pipeline called AASsites</article-title><source>BMC Bioinformatics</source><year>2011</year><volume>12</volume><issue>Suppl 4</issue><fpage>S2</fpage><pub-id pub-id-type="pmid">21992029</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>JD</given-names></name><name><surname>Sheahan</surname><given-names>PJ</given-names></name><name><surname>Lai</surname><given-names>D</given-names></name><name><surname>Kril</surname><given-names>JJ</given-names></name><name><surname>Janitz</surname><given-names>M</given-names></name><etal/></person-group><article-title>The alternative splicing of the apolipoprotein E gene is
unperturbed in the brains of Alzheimer&#x02019;s disease
patients</article-title><source>Mol Biol Rep</source><year>2014</year><volume>41</volume><fpage>6365</fpage><lpage>6376</lpage><pub-id pub-id-type="pmid">24996286</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gryaznov</surname><given-names>S</given-names></name><name><surname>Skorski</surname><given-names>T</given-names></name><name><surname>Cucco</surname><given-names>C</given-names></name><name><surname>Nieborowska-Skorska</surname><given-names>M</given-names></name><name><surname>Chiu</surname><given-names>CY</given-names></name><etal/></person-group><article-title>Oligonucleotide N3&#x02019;--&#x0003e;P5&#x02019;
phosphoramidates as antisense agents</article-title><source>Nucleic Acids Res</source><year>1996</year><volume>24</volume><fpage>1508</fpage><lpage>1514</lpage><pub-id pub-id-type="pmid">8628685</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeVos</surname><given-names>SL</given-names></name><name><surname>Miller</surname><given-names>TM</given-names></name></person-group><article-title>Antisense oligonucleotides: treating neurodegeneration at the
level of RNA</article-title><source>Neurotherapeutics</source><year>2013</year><volume>10</volume><fpage>486</fpage><lpage>497</lpage><pub-id pub-id-type="pmid">23686823</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaida</surname><given-names>D</given-names></name><name><surname>Berg</surname><given-names>MG</given-names></name><name><surname>Younis</surname><given-names>I</given-names></name><name><surname>Kasim</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>LN</given-names></name><etal/></person-group><article-title>U1 snRNP protects pre-mRNAs from premature cleavage and
polyadenylation</article-title><source>Nature</source><year>2010</year><volume>468</volume><fpage>664</fpage><lpage>668</lpage><pub-id pub-id-type="pmid">20881964</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>B</given-names></name><name><surname>Hales</surname><given-names>CM</given-names></name><name><surname>Chen</surname><given-names>PC</given-names></name><name><surname>Gozal</surname><given-names>Y</given-names></name><name><surname>Dammer</surname><given-names>EB</given-names></name><etal/></person-group><article-title>U1 small nuclear ribonucleoprotein complex and RNA splicing
alterations in Alzheimer&#x02019;s disease</article-title><source>Proc Natl Acad Sci U S A</source><year>2013</year><volume>110</volume><fpage>16562</fpage><lpage>16567</lpage><pub-id pub-id-type="pmid">24023061</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leroy</surname><given-names>K</given-names></name><name><surname>Ando</surname><given-names>K</given-names></name><name><surname>Laporte</surname><given-names>V</given-names></name><name><surname>Dedecker</surname><given-names>R</given-names></name><name><surname>Suain</surname><given-names>V</given-names></name><etal/></person-group><article-title>Lack of tau proteins rescues neuronal cell death and decreases
amyloidogenic processing of APP in APP/PS1 mice</article-title><source>Am J Pathol</source><year>2012</year><volume>181</volume><fpage>1928</fpage><lpage>1940</lpage><pub-id pub-id-type="pmid">23026200</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>VB</given-names></name><name><surname>Farr</surname><given-names>SA</given-names></name><name><surname>Flood</surname><given-names>JF</given-names></name><name><surname>Kamlesh</surname><given-names>V</given-names></name><name><surname>Franko</surname><given-names>M</given-names></name><etal/></person-group><article-title>Site-directed antisense oligonucleotide decreases the expression
of amyloid precursor protein and reverses deficits in learning and memory in
aged SAMP8 mice</article-title><source>Peptides</source><year>2000</year><volume>21</volume><fpage>1769</fpage><lpage>1775</lpage><pub-id pub-id-type="pmid">11150636</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Alternative splicing patterns that may occur in AD</title><p id="P22">The colored boxes are exons and gray boxes are introns. The black
connection lines show the different patterns of including or excluding exons to
generate different splicing products.</p></caption><graphic xlink:href="nihms721348f1"/></fig><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><p id="P23">Alternatively spliced genes and their associated effects in AD.</p></caption><table frame="box" rules="all"><thead><tr><th align="left" rowspan="1" colspan="1">Protein</th><th align="center" rowspan="1" colspan="1">Gene Affected</th><th align="center" rowspan="1" colspan="1">Exon Spliced</th><th align="center" rowspan="1" colspan="1">Observation</th><th align="center" rowspan="1" colspan="1">Method</th><th align="center" rowspan="1" colspan="1">Ref</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>APBB2</bold></td><td align="center" rowspan="1" colspan="1"><italic>APP</italic></td><td align="center" rowspan="1" colspan="1">Exon 8 Exclusion</td><td align="center" rowspan="1" colspan="1">Increase in beta-amyloid release</td><td align="center" rowspan="1" colspan="1">RT-qPCR</td><td align="center" rowspan="1" colspan="1">[<xref rid="R10" ref-type="bibr">10</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>RBFox</bold></td><td align="center" rowspan="1" colspan="1"><italic>APP</italic></td><td align="center" rowspan="1" colspan="1">Exon 7 Exclusion</td><td align="center" rowspan="1" colspan="1">Increase in beta-amyloid production</td><td align="center" rowspan="1" colspan="1">RT-qPCR</td><td align="center" rowspan="1" colspan="1">[<xref rid="R15" ref-type="bibr">15</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Presenilin 1</bold></td><td align="center" rowspan="1" colspan="1"><italic>PSEN1</italic></td><td align="center" rowspan="1" colspan="1">Exon 4 Exclusion</td><td align="center" rowspan="1" colspan="1">Improper cleavage of APP increasing beta-amyloid
deposition.</td><td align="center" rowspan="1" colspan="1">RT-qPCR</td><td align="center" rowspan="1" colspan="1">[<xref rid="R16" ref-type="bibr">16</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Presenilin 2</bold></td><td align="center" rowspan="1" colspan="1"><italic>PSEN2</italic></td><td align="center" rowspan="1" colspan="1">Exon 5 Exclusion</td><td align="center" rowspan="1" colspan="1">Improper cleavage of APP increasing beta-amyloid
deposition.</td><td align="center" rowspan="1" colspan="1">RT-qPCR</td><td align="center" rowspan="1" colspan="1">[<xref rid="R16" ref-type="bibr">16</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Apolipoprotein E</bold></td><td align="center" rowspan="1" colspan="1"><italic>APOE</italic></td><td align="center" rowspan="1" colspan="1">Exon 5 Exclusion</td><td align="center" rowspan="1" colspan="1">Increase beta- amyloid deposition, and or affecting tau
structure.</td><td align="center" rowspan="1" colspan="1">RNA-Seq</td><td align="center" rowspan="1" colspan="1">[<xref rid="R11" ref-type="bibr">11</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Tau</italic></bold></td><td align="center" rowspan="1" colspan="1"><italic>MAPT</italic></td><td align="center" rowspan="1" colspan="1">Exon 10 Inclusion</td><td align="center" rowspan="1" colspan="1">Generating an imbalance of 3R-<italic>tau</italic> and
4R-<italic>tau</italic> leading to <italic>tau</italic> protein
aggregation.</td><td align="center" rowspan="1" colspan="1">RT-qPCR</td><td align="center" rowspan="1" colspan="1">[<xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>